Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Genitourinary 2Gastrointestinal 2Sarcoma 1Other hematologic neoplasm 1Other 1Lymphoid 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Skin Neoplasms 1Melanoma 1Gastrointestinal Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Aromatherapy × Dermatologic × Clear all
NCT03858855 2020-08-04

Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment

Ohio State University Comprehensive Cancer Center

Phase NA Completed
248 enrolled
DermatologicEndocrineGastrointestinal

Gastrointestinal Neoplasms, Melanoma, Skin Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡